{"name":"Zenas BioPharma (USA), LLC","slug":"zenas-biopharma-usa-llc","ticker":"","exchange":"","domain":"zenasusallc.com","description":"Zenas BioPharma (USA), LLC is a biotechnology company focused on developing innovative therapies in the early stages of clinical development. With a pipeline of three drugs all in Phase 1, the company is investing heavily in research and development despite reporting a net loss.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":10000000,"revenueGrowth":100,"grossMargin":0,"rdSpend":168063000,"netIncome":-377737000,"cash":383640000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNMHBLM3I3M2F0STgweEpKbmhqX0VXXzZ1U1BBYXNZbzNCX3FYQlNNUkdLdk1nM0VRcFVQTHBRTkFsLW5yVEFXZU5oekpsanV4ZW5DUVBhcXExbF90ajVSNHZ2YW9kSThpX1pPRnNJSGdlcmYwUG1IWV9WR01EOWF3MlUzM0g4cEFYa2dSTi1DdG05ZVlGOTV5RmNfd2t2STNTd0NWVnNzYU9nRjZCb01SUjcyNWRRZFY4U3ZBOGJiN0RMMVlIVl9UcmlR?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"Leon Moulder boosts Zenas BioPharma (ZBIO) stake to 4.794% ownership - Stock Titan","headline":"Leon Moulder boosts Zenas BioPharma (ZBIO) stake to 4.794% ownership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNN29RcXVNSlNsclcyQk5sRnJVVjNLV1JqUlp5RzFic19tLV9mY1lEQVlnMjhoanptU3JLZjV2NTU4aTFEWGJxeGxwUWFGQ2hZYklxUm1fejNtcnVjV3QwcHNBZDVHUFJlMnVVX29OTl9TaTJ5bnFLbVV6TzRMMU5OR2FwR0dnMGFRS3JSczd4YW9xUnIwbDktR054VXNVOXVzX19zRGRqcUYwUk9rWlVkTW8wOEI?oc=5","date":"2026-04-02","type":"pipeline","source":"Stock Titan","summary":"Zenas BioPharma (ZBIO) director-affiliated funds purchase 3,768 shares - Stock Titan","headline":"Zenas BioPharma (ZBIO) director-affiliated funds purchase 3,768 shares","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOUVBVOV9LYlZwT1RiQWYyazA2amNmUTZvdXkxNXdtd2h1NmNrdzRDVXZBR09XUHdObG5hVWFHRUVlaXFZdVFXbTZuUVEta3ZLRFJzSnRrUktVSlhRekZBU0JEQkRkUlVnYUF0OENMYm1DS3MzUXNFaDgtV3JtdlJZdE8xUllmbGVOeXV1NVhrVGMwa0ExaWNsSVRSYXcyWTdVSDlnampkUERWdzE2MmVrMEJKMUpGV3M0bEdVeU84QVVmUQ?oc=5","date":"2026-03-21","type":"pipeline","source":"The Motley Fool","summary":"ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch - The Motley Fool","headline":"ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch","sentiment":"neutral"},{"date":"2026-03-16","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOU3hfa0JPVU9zTXZWc1A0WkRUYVhLZlB3c1RPc1FxVU1mSFBlN0lQT0tOMHlvbXJwRlZMbFhxdV9zTkxfWXBkUFdGcWZaQkFRMHpNMWFvUGpTVjlHZzluYXp4QXI5TlJrT0NXR2JwMGFrd3hZeFdyUzVuR0NuZnVuSkEzdjRRUEFqWXhPUjhsRXBEeUFIZl9jLVc1VVoyaHRmWFRVTWw0S3pFOV9xMlYzU2RpR2ZEV1dieWpjRTd4eElFY2V6UkdhdWNOd0NUUXk1Um95SjhVNHRRRUxXNGtzc2d4a2NkcjN3YmlUWEZCWTlkc2U4YlNyMW50XzFzdw?oc=5","date":"2026-02-16","type":"trial","source":"Investing News Network","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Investing News Network","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-24","type":"earnings","source":"simplywall.st","summary":"Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher - simplywall.st","headline":"Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNYjFvNmpsSi01OEVKcU1UendvVHYyWEVqWFF5T0doUGJNTmxlLXlrSVJUalF2Y3lURUNyMmFlRmlabFI4MlhLNlJMbENpbl9OMVJLOURwcHNzbkhyQ2VxcFZrSHItMl9SQ2ZMQ0ZZbzJscEdXeFg5YzlMZUpNVnZVQ01pZllLX3lnbmdnelZFbDZxcFJpYVRtNVMzNA?oc=5","date":"2025-10-24","type":"deal","source":"Streetwise Reports","summary":"US Biopharma In-Licenses 3 New Assets - Streetwise Reports","headline":"US Biopharma In-Licenses 3 New Assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcHRlT1lSSWxFZVFQWFhFRlFqcnFteFBiSnJjc3ZLMl9XUWRFcERwNVZheDNFZnJUTzNGWnVnSlJmYVJaUWpNTi1OX2EtTElkT2ZVYzhDSEJpRmVFdmMySmlaU1lrZ296V1RqUVhYZlpxWW5SUUtaT0pubENwbUZVV2JtYWY0aEhnUGpSMmE5UXh6Sl9FY3BDQy1jVUJyeWJzYW40akdRMVJCOGxuRHM3QUE0N0ZrVHUyMlhuOTNfdUhzQmVURUR6d2JuVTluemxpRkxaSmxudjFjdw?oc=5","date":"2025-10-08","type":"deal","source":"Reuters","summary":"Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters","headline":"Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOU1VfUnJXTE5fTUNGa1VoMk1oQzlWT28zRzdVUTkzaVJDYS1qbjh6VGlGSDZVRUdBWHRQakRqbUYxNmtCdTZ5N1VJOG5scVhnVWFRUThlS01yV3UxT3hZaHhwLUFIb1RaeTUyX0NuUXJPSURmS09OeGY1ck8tUF84T1JnS2NRMnoyYkFzbVNacGo3QzUtUHUweUEwVDR3Rm04?oc=5","date":"2025-10-08","type":"deal","source":"Fierce Pharma","summary":"Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCare - Fierce Pharma","headline":"Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCare","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-08","type":"deal","source":"GlobeNewswire","summary":"Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire","headline":"Zenas BioPharma and InnoCare Pharma Announce License","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOZjY1SHZXdG1yekpHTTBEWlhtV1dqTHg4a05JY2kzSlh3b20wY1JMUGt0TW1CRlhCbFM2bHkzdUJ4VkxIQ2Q1OTFNeTBaMW05QUlHMFlLWVUtaVp4RE5MMnAzZUowQmZIdm52UmVPRmRTaDBsTHVhTGF1aE9jMmJ0M1RWU0RJSTdYVXlZWW5STWNDcXNZUDBhT3Z4QmRBWHI3a3I4QkFB?oc=5","date":"2025-10-08","type":"deal","source":"BioWorld News","summary":"Zenas gets global rights for Innocare BTK inhibitor in $2B+ deal - BioWorld News","headline":"Zenas gets global rights for Innocare BTK inhibitor in $2B+ deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxPTW5WNnF3QkRTRFQ0cDRJSEpKQnE4ZUJQTVdtRW42enlJLUFvdjVDVHVQM25SdDQtc1ZkbFlOWmFUS0tISFpZRTZOMmx6VTJ6Y3pReUctZmozSTEtZFFyMmZrY2ZZSy02TVNJcm9XWlpOZVg3cWpCbjRDQUxjektjeXpIU3lHQnZkSjhqMVpYOXBDQ2pkTEZOQWFJVGtmN0szU3ViUTl2eEM5M2tJcm1zZXk3LWlKOWxnZy1rZXV4X1A5WlJCZ0tKNGx1dVpKRDJQZ2l2dldqX29veDN6cEduMlNhU3NWdmxNeTRBNkEzSXVENXVlSEFqY3lITzJERzQ?oc=5","date":"2025-09-12","type":"deal","source":"Citeline News & Insights","summary":"The Rise In China Deals: How International Biopharma Is Turning To China For Innovation - Citeline News & Insights","headline":"The Rise In China Deals: How International Biopharma Is Turning To China For Innovation - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWUVzYVJhLTdHVFBfbkJzRURtTGNtbkJreDEyR2FBbjRsUmtpdEhFd2xJak8tYUhJR1p3VGlZX1RPZ3BMRzhhTlhGRmZTTW1jUF9fbzNEOTU5aUxSMXpQUDBEU205WWhCRUFBTXlFa1RSMzVuUWJnaWw3QmFSelhodkRKaGZVYXFIOTRCZUxHc2tYTnFpYWVaYmZMLUFSTHY1V3NxNk9jTnhGMkM3YnZXXzRlNXFLVllxOWlR?oc=5","date":"2025-09-02","type":"regulatory","source":"Fierce Biotech","summary":"Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line - Fierce Biotech","headline":"Royalty bestows Zenas with $300M deal to push autoimmune asset across FDA finish line","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":10000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":10000000,"period":"2025-12-31"},{"value":5000000,"period":"2024-12-31"},{"value":5000000,"period":"2024-12-31"},{"value":50000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":168063000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-377737000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":383640000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}